Developing a model to predict accrual to cancer clinical trials: Data from an NCI designated cancer center
Praveena Iruku(University of Colorado Health), Virginia Kaklamani(Northwestern University), Jenny C. Chang(Universität Hamburg), Susan S. Padalecki(The University of Texas at San Antonio Health Science Center), Martin Goros(The University of Texas at San Antonio Health Science Center), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Jonathan Gelfond(The University of Texas at San Antonio Health Science Center)
Cited by 8
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Genetic/Familial High-Risk Assessment: Breast and Ovarian
|Journal of the National Comprehensive Cancer Network|2010|650
Mortality in vegetarians and nonvegetarians: detailed findings from a collaborative analysis of 5 prospective studies
|American Journal of Clinical Nutrition|1999|488